respiratori
infect
major
caus
morbid
mortal
human
infect
caus
respiratori
virus
sever
unpreced
epizoot
avian
influenza
virus
eg
cross
speci
barrier
caus
human
death
sever
acut
respiratori
syndrom
coronaviru
sarscov
recent
middl
east
respiratori
syndrom
coronaviru
merscov
coronavirus
also
pose
major
threat
medic
public
health
system
moreov
human
human
metapneumoviru
enteroviru
bunyavirus
common
respiratori
virus
respiratori
syncyti
viru
parainfluenza
virus
rhinovirus
human
influenza
gangster
respiratori
diseas
continu
emerg
new
reemerg
viral
threat
emphas
unpredict
pathogen
bring
challeng
develop
control
strategi
although
vaccin
remain
mileston
prevent
viral
infect
homolog
vaccin
avail
first
pandem
wave
newli
emerg
virus
furthermor
continu
antigen
drift
antigen
shift
viru
lead
escap
recognit
immun
system
inefficaci
protect
host
novel
antigen
variant
thu
antivir
novel
pharmacolog
activ
highli
need
sever
antivir
agent
develop
agent
undergo
clinic
trial
differ
stage
preclin
develop
vast
major
yet
approv
clinic
use
sever
challeng
block
develop
antivir
well
applic
review
focu
problem
prospect
antivir
develop
control
newli
emerg
reemerg
respiratori
virus
pandem
potenti
develop
nucleic
acid
amplif
techniqu
naat
method
enabl
detect
low
concentr
viral
nucleic
acid
moreov
naat
avail
method
newli
emerg
respiratori
virus
tradit
test
lack
effici
cellcultur
system
antigen
detect
method
current
autom
multiplex
naat
develop
make
easier
obtain
laboratori
diagnost
result
techniqu
anticip
use
costeffect
assess
antivir
respiratori
viru
seri
antivir
discov
develop
control
respiratori
viru
infect
agent
target
essenti
step
viral
infect
includ
viral
attach
endocytosi
replic
assembl
bud
releas
other
directli
target
viru
intracellular
pathway
essenti
viral
replic
attach
process
critic
step
virus
gain
entri
cell
block
interact
viralspecif
surfac
protein
cellreceptor
promis
strategi
develop
novel
antivir
sialidas
amphiregulin
glycosaminoglycan
recombin
construct
ansun
biopharma
inc
san
diego
ca
hydrolyz
sialic
acid
receptor
respiratori
epithelium
cell
surfac
thu
effici
block
attach
human
avian
influenza
viru
confirm
antivir
activ
vitro
vivo
moreov
phase
ii
clinic
trial
confirm
significantli
reduc
viral
load
viral
shed
compar
placebo
group
p
p
multipledos
singledos
group
respect
advanc
clinic
develop
prospect
treatment
human
avian
influenza
infect
n
naae
small
molecul
inhibit
interact
sarscov
spike
protein
cell
surfac
receptor
angiotensin
convert
enzym
howev
inhibit
naae
also
potenti
risk
hypertens
henc
viral
receptor
also
import
cell
function
agent
util
mechan
might
caus
side
effect
host
sever
human
monoclon
antibodi
develop
block
viral
attach
cell
human
monoclon
antibodi
protect
ferret
lethal
challeng
highli
pathogen
avian
viru
prophylact
therapeut
administr
compar
surviv
control
group
p
motavizumab
palivizumab
confirm
prevent
particip
respiratori
syncyti
viru
infect
independ
clinic
trial
show
motavizumab
treatment
effect
durat
hospit
sever
ill
measur
wheez
episod
followup
among
children
infect
respiratori
syncyti
viru
compar
placebo
treatment
despit
inconsist
clinic
data
human
monoclon
antibodi
high
cost
biolog
also
formid
problem
therapi
infect
pharmacolog
inhibit
endocytosi
process
viral
envelop
cell
membran
also
promis
strategi
develop
antivir
endocytosi
process
respiratori
viru
subdivid
three
step
intern
fusion
uncoat
inhibit
process
achiev
follow
mechan
block
pathway
facilit
viral
intern
suppress
acidif
endosom
reduc
membran
curvatur
fluiditi
interf
conform
chang
viral
protein
requir
fusion
viral
uncoat
inhibit
numer
broadspectrum
antivir
develop
purpos
dynamindepend
dynaminindepend
pathway
consid
rout
influenza
cell
intern
inhibitor
pathway
includ
cytochalasin
b
jasplakinolid
latruncul
specif
inhibitor
intern
influenza
accumul
evid
confirm
activ
promot
viru
intern
interplay
influenza
viru
receptor
tyrosin
kinas
rtk
host
cell
promot
pathway
facilit
viral
uptak
howev
one
cautiou
potenti
benefit
rtk
inhibitor
potenti
antivir
agent
limit
number
rtk
manipul
chemic
inhibitor
sirna
time
envelop
virus
lowph
environ
endosom
trigger
fusion
endosom
virion
also
caus
dissoci
viral
ribonucleoprotein
complex
vrnp
capsid
allow
subsequ
import
nucleu
start
viral
replic
thu
block
endosom
acidif
also
interfer
viral
infect
saliphenylhalamid
concanamycin
archazolid
b
diphyllin
bafilomycin
endosom
acidif
inhibitor
may
abrog
influenza
viral
infect
inhibit
cellular
vacuolar
atpas
vatpas
vacuolartyp
proton
vh
pump
endosom
among
saliphenylhalamid
saliph
effect
inhibit
sever
wild
type
influenza
virus
includ
pandem
swineorigin
influenza
viru
highli
pathogen
avian
influenza
viru
oseltamivirresist
season
influenza
viru
moreov
protect
mice
lethal
challeng
mouseadapt
influenza
strain
thu
endosom
acidif
inhibitor
even
better
select
indic
may
becom
candid
treatment
viral
infect
futur
membran
curvatur
fluiditi
critic
viralendosom
membran
fusion
lipophil
thiazolidin
deriv
inhibit
membran
curvatur
fluiditi
mediat
lipid
oxid
exhibit
broadspectrum
antivir
activ
envelop
virus
includ
influenza
viru
bunyavirus
ebola
rift
valley
fever
virus
led
new
class
membranetarget
photosensit
increas
potenc
antivir
research
arbidol
anoth
broadspectrum
antivir
antifus
activ
stabil
surfac
glycoprotein
influenza
viru
hemagglutinin
ha
lowph
form
agent
prove
activ
sever
subtyp
avian
influenza
vitro
smallmolecul
inhibitor
interfer
rsv
fusion
interact
f
protein
respiratori
syncyti
viru
phase
develop
note
entri
sever
highli
pathogen
virus
sarscov
ebola
viru
host
cell
depend
cathepsin
l
facilit
fusion
viral
envelop
cellular
membran
viral
attach
thu
small
molecul
prevent
cathepsin
l
cleavag
would
anticip
amelior
sever
respiratori
viral
infect
also
agent
target
uncoat
process
process
influenza
requir
coordin
action
viral
protein
tetram
present
virion
possess
select
h
ionchannel
activ
allow
uncoat
viru
particl
endosom
two
commerci
avail
inhibitor
amantadin
rimantadin
wide
use
treatment
human
avian
influenza
infect
mani
year
unfortun
current
human
avian
influenza
virus
amantadineor
rimantadineresist
due
drug
overus
howev
wang
et
al
offer
glimmer
hope
develop
inhibitor
discov
novel
proton
channel
inhibitor
effect
wildtyp
preval
drugresist
mutant
influenza
viru
rna
polymeras
essenti
replic
rna
virus
inhibitor
specif
viral
rna
polymeras
would
exhibit
antivir
activ
affect
mrna
synthesi
protein
translat
host
cell
favipiravir
one
agent
select
inhibit
viral
rna
polymeras
sever
influenza
strain
respiratori
syncyti
viru
ebola
viru
moreov
favipiravir
effect
protect
mice
lethal
infect
highli
pathogen
influenza
viru
phase
ii
clinic
trial
unit
state
novel
compound
etc
develop
inhibit
polymeras
influenza
virus
moreov
inhibitor
exhibit
broadspectrum
antivir
activ
variou
respiratori
virus
includ
influenza
virus
respiratori
syncyti
viru
paramyxovirus
coronavirus
bunyavirus
make
particularli
attract
research
target
ribavirin
inosin
imp
dehydrogenas
involv
viral
rna
synthesi
cellular
biosynthesi
gtp
ribavirin
exhibit
effici
avian
influenza
activ
vitro
rang
treatment
ribavirin
po
bid
protect
mice
lethal
infect
howev
clinic
efficaci
ribavirin
toward
influenza
limit
mode
deliveri
aerosol
ribavirin
exhibit
effect
inhibitori
activ
influenza
virus
respiratori
syncyti
virus
clinic
observ
oral
administ
ribavirin
moreov
clinic
util
ribavirin
restrain
risk
hemolyt
anemia
teratogen
prodrug
ribavirin
viramidin
anticip
solv
problem
prodrug
similar
antivir
activ
ribavirin
less
toxic
drug
phase
iii
develop
hepat
c
viru
hcv
treatment
dihydroorot
dehydrogenas
dhodh
key
enzym
essenti
replic
viral
rna
dna
biosynthesi
de
novo
pyrimidin
gener
uracil
inhibitor
compound
etc
target
dhodh
found
inhibit
replic
rna
dna
respiratori
virus
influenza
viru
adenoviru
proteas
proteinas
viru
also
attract
target
develop
antivir
agent
papainlik
proteas
plp
protein
take
part
format
polyprotein
sarscov
replic
proteas
inhibitor
exhibit
antirepl
acit
sarscov
influenza
viru
vitro
helicas
viru
protein
unpackag
duplex
oligonucleotid
singl
strand
bananin
helicas
inhibitor
confirm
effici
inhibitor
sarscov
replic
vitro
valu
rang
sinc
sever
respiratori
virus
replic
genom
nucleu
infect
cell
newli
synthes
vrna
togeth
rna
polymeras
nucleoprotein
form
vrnp
export
cytoplasm
assembl
process
depend
seri
pathway
pathway
leptomycin
b
potent
inhibitor
export
leptomycin
b
treatment
lead
decreas
export
influenza
vrnp
nucleu
howev
leptomycin
b
toxic
vivo
limit
therapeut
use
verdinexor
novel
select
vrnpexport
inhibitor
target
homolog
verdinexor
effect
inhibit
replic
variou
influenza
stain
includ
pandem
influenza
viru
highli
pathogen
newli
emerg
avian
influenza
virus
moreov
prophylact
therapeut
administr
verdinexor
effect
protect
mice
influenza
infect
thu
verdinexor
promis
candid
deserv
clinic
investig
nitazoxanid
approv
antiparasit
agent
also
prevent
ha
transport
influenza
viru
cell
surfac
interf
ha
traffick
endoplasm
reticulum
golgi
complex
moreov
nitazoxanid
confirm
broadspectrum
antivir
rna
dna
virus
vitro
current
nitazoxanid
clinic
develop
treatment
influenza
influenza
viru
bud
event
initi
deform
membran
caus
cluster
ha
na
bind
cytoplasm
tail
ha
na
recruit
vrnp
form
interior
structur
emerg
virion
site
viru
bud
subsequ
alter
membran
curvatur
neck
bud
viru
caus
membran
scission
initi
releas
progeni
virion
thu
inhibitor
mention
may
also
inhibit
bud
influenza
viru
cyclophilin
inhibitor
cyclosporin
also
inhibit
propag
influenza
viru
interf
assembl
bud
influenza
viru
besid
interf
viral
rna
synthesi
cell
final
releas
process
influenza
viru
na
enabl
progeni
viru
cleav
receptor
spread
cell
thu
na
inhibitor
prevent
influenza
spread
block
releas
progeni
virion
four
commerci
na
inhibitor
oseltamivir
zanamivir
peramivir
laninamivir
approv
use
human
among
na
inhibitor
laninamivir
extrem
long
persist
time
lung
increas
prospect
longact
antivir
effect
prevent
influenza
infect
singl
dose
emerg
nainhibitorresist
influenza
strain
substanti
challeng
antivir
therapi
futur
although
direct
evid
confirm
develop
resist
correl
wide
use
oseltamivir
resist
virus
would
acquir
chanc
transmiss
drugselect
pressur
compar
drugsensit
strain
asid
agent
directli
target
viral
protein
current
antivir
strategi
also
focu
intracellular
pathway
essenti
viral
replic
rafmekerk
pkc
signal
pathway
might
promis
target
antivir
approach
sinc
pathway
also
critic
cytokin
interferon
synthesi
viral
infect
inhibitor
target
cascad
may
inhibit
viral
replic
also
subsequ
inflamm
viral
infect
moreov
compound
target
extrem
low
risk
emerg
drugresist
variant
thu
inhibitor
intracellular
pathway
promis
candid
treatment
respiratori
virus
develop
pursu
herb
may
also
potenti
choic
patient
hospit
respiratori
virus
sever
chines
herbal
prescript
recommend
author
chines
govern
sarscov
influenza
avian
influenza
pandem
blanco
consid
heatclear
detoxifi
properti
accord
theoret
system
tradit
chines
medicin
antivir
mechan
herbal
medicin
fulli
elucid
howev
data
suggest
activ
compon
exhibit
actual
antivir
activ
addit
report
extract
jiaweiyupingfengtang
tradit
chines
herbal
formula
exhibit
antirespiratori
viral
activ
also
confirm
green
teaderiv
polyphenol
epigallocatechin
gallat
egcg
inhibit
influenza
viru
antioxid
activ
data
suggest
herbal
medicin
may
reservoir
antivir
develop
nevertheless
current
confirm
herbal
therapi
still
insuffici
owe
lack
data
random
control
clinic
trial
persist
outbreak
respiratori
viral
infect
world
suggest
respiratori
viral
pathogen
continu
import
threat
human
health
similar
clinic
symptom
respiratori
viral
infect
rapid
sensit
diagnos
essenti
earli
viral
identif
subsequ
costeffect
monitor
antivir
clinic
trial
autom
multiplex
naat
may
help
solv
problem
method
anticip
gener
applic
futur
still
mani
challeng
unansw
question
develop
antivir
sever
potent
agent
develop
target
viral
protein
cellular
factor
essenti
viru
replic
howev
gener
yet
pass
clinic
trial
show
antivir
evid
human
hand
exist
antivir
therapi
also
face
challeng
drug
resist
nonspecif
side
effect
therefor
urgent
need
novel
drug
combin
therapi
effort
made
design
develop
new
antivir
specif
target
basic
step
viral
life
cycl
includ
attach
endocytosi
replic
assembl
bud
releas
cellular
process
efficaci
viral
resist
mutual
effect
toxic
combin
usag
antivir
need
clarifi
